Intravitreal Aflibercept for Diabetic Macular Edema

To compare efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for diabetic macular edema (DME) over 3 years.Two similarly designed phase 3 trials: VISTADME and VIVIDDME.Patients (eyes; n = 872) with central-involved DME.Eyes received IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or laser control. From week 24, if rescue treatment criteria were met, IAI patients...